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Mupirocin Pemphigus-Like Drug Reaction in a Dog
Tiago Cunha Ferreira, Rodrigo Fonseca de Medeiros Guedes,  
Belise Maria Oliveira Bezerra & Diana Célia Sousa Nunes-Pinheiro
Background: Pharmacodermia is defined as adverse reaction in skin, mucosa and appendages, which generates morpho-
functional alterations in cutaneous barrier, inducing autoimmune diseases, such as pemphigus foliaceous, which is known as 
the most common autoimmune skin disease in dogs. This disease involves autoantibodies against desmoglein and desmocolin 
molecules, being induced by the use of certain drugs. Mupirocin (pseudomonic acid A) is a broad-spectrum antibiotic with 
bacteriostatic activity, being effective against Gram-positive pathogens and used to control superficial bacterial folliculitis. 
Based on that, the aim of this study was to report a pemphigus-like lesions after topical use of mupirocin in dog.
Case: An 1-year-old, uncastrated male, Poodle dog, weighing 13.8 kg was treated in a private clinic in Fortaleza. The main 
complaint was related to pruritus in abdominal and inguinal region, in addition of legs licking. Dermatological examina-
tion revealed melanic crusts, epidermal collars and diffuse pustules in inguinal, abdominal, perianal and thoraco-lumbar 
regions. The therapy was based on topical use of Mupirocin in form of 0.2% aquous spray. After drug administration, the 
animal presented urticaria, diffuse epidermal collars, papulo-crusted and pustular lesions, which were more evident in 
abdominal and inguinal region. Nasal erythema, binocular blepharitis, apathy and fever were also observed. Cytological 
examination and bacterial culture were performed, revealing inflammatory and acantholytic cells and no bacterial growth. 
Biopsy procedure revealed subcorneal pustule with presence of epithelial acantholytic cells and neutrophils, compatible 
with canine pemphigus foliaceous. The topical treatment of ocular lesions with 0.1% Tacrolimus associated with systemic 
treatment with high dose of prednisolone (1.2 mg kg-1). The patient improved the dermatological clinical signs, however, 
some side effects have already become evident, such as the presence of telangiectasia, polyuria, polyphagia and polydipsia. 
Heterodox therapy based on the use of azathioprine (2 mg kg-1) was chosen in order to reduce corticoid dose. After 3 days 
of therapy, blood material was collected for hepatic evaluation, detecting hepatotoxicity. From the results, azathioprine 
therapy was suspended, and only high-dose corticosteroid therapy (1.5 mg kg-1) was maintained. The patient presented a 
considerable improvement in the lesion after 10 days of treatment.
Discussion: There have been reports that pharmacodermic reactions may be associated with the development of autoim-
mune diseases, such as pemphigus foliaceus and vulgaris. In some cases, the lesions regress after drug discontination. 
In others, the medication acts as a triggering factor, activating the genetic predisposition of patient, which develops the 
pathology even after therapy interruption. The drug related pemphigus-foliaceous is a well-recognized disease in humans, 
however this disease is limited to sporadic cases in dogs. The therapy was based in use of a high dose of prednisolone, 
which caused some side effects. Therefore, a heterodox therapy was chosen in order to reduce the corticoid dosage. At 
the first hemato-biochemical evaluation, the patient already presented significant alterations, being requested to suspend 
the prescribed treatment, although the owners already reported improvement of the dermatological lesions. Due to this, a 
higher dose of prednisolone was chosen, obtaining the best response among the therapies used since the beginning of the 
treatment. After clinical improvement, the gradual reduction of steroidal therapy was started in order to avoid side effects 
related to suppression of the hypothalamic-pituitary-adrenal axis. This report provides evidences of Mupirocin as a potential 
triggering factor of pemphigus-like lesions in dogs.
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INTRODUCTION
Pharmacodermic reactions are defined as ad-
verse manifestations in skin, mucosa and appendages 
due to topical or systemic drugs, which may cause 
structural or functional alterations in skin, reflecting 
on localized or generalized lesions [6,13,22]. These 
reactions can also trigger the development of autoim-
mune diseases, such as pemphigus foliaceous (PF), in 
predisposed individuals, which can progress even after 
drug discontinuation [10].
PF is known as the most common autoimmune 
skin disease in dogs, involving naturally or induced 
autoantibodies production against desmoglein and 
desmocolin molecules [1,3]. Iatrogenic PF is subdi-
vided in drug-induced, which drug discontinuance 
leads to disease regression, or drug-triggered, where 
the drug stimulates the disease natural development 
and progression [10,24]. PF caused by drugs is well 
described in humans, associated to different drugs, 
such as angiotensin converting enzymes inhibitors and 
antibiotics [21].
Mupirocin (pseudomonic acid A) is a broad-
spectrum antibiotic with bacteriostatic activity, being 
effective against Gram-positive pathogens, specially 
staphylococci and streptococci [7]. In dogs, it is used 
to control superficial bacterial folliculitis [8], showing 
a low prevalence of resistance [16].
Considering the lack of reports about drug-
related PF in dogs [9], the objective of the present 
study is to describe the occurrence of pemphigus-like 
lesions in consequence of a pharmacodermic reaction 
following a topical application of mupirocin.
CASE
An 1-year-old, uncastrated male, Poodle dog, 
weighing 13.8 kg was treated in a private clinic in 
Fortaleza. The main complaint was related to pruritus 
in abdominal and inguinal region, in addition of legs 
licking. At the general clinical examination, the follow-
ing observations were made: active patient, hydrated, 
temperature of 38.7ºC and non-palpable lymph nodes. 
No ectoparasites were seen. Dermatological examina-
tion revealed meliceric crusts, epidermal collars and 
diffuse pustules in the inguinal, abdominal, perianal 
and thoraco-lumbar regions (Figure 1A). The legs 
were erythematous, as were the ears. Areas of alope-
cia were not visualized. The hairs were clean and the 
skin slightly oily. Therefore, through the information 
collected in anamnesis and clinical examination, the 
use of topical therapy with mupirocin (Bactroban®)1 in 
form of 0.2% aqueous spray, BID, for 15 days.
After initiation of treatment, the patient pre-
sented lesion worsening, such as increased quantity 
and size of epidermal pustules and collars, besides the 
appearance of urticaria and papular-crusted lesions 
in diffuse areas of the body, being more evident in 
abdominal and inguinal regions (Figure 1B).
On the occasion, cytological examination and 
bacterial culture were performed with material from 
the secretion of meliceric crusts and epidermal collars. 
Inflammatory cells were characterized, mostly, by in-
tact and rare degenerated neutrophils, interspersed with 
acantholytic cells (Figure 2A). Regarding the bacterial 
culture, there was no growth of any bacteria from the 
collected sample. From the data, it was suspected of 
pharmacodermia related to mupirocin, being requested 
the drug suspension and added immunosuppressive 
drugs to treatment protocol. After the exchange of the 
previously adopted therapy, the patient improved the 
clinical picture, showing remission of the lesions and 
pruritus (Figure 1C/1D).
Figure 1. Aspects of skin lesions before (A) and 4 days after (B) topical 
use of mupirocin. Treatment after cutaneous mupirocin drug reaction - 07 
days (C) and 15 days (D). [Source: T.C. Ferreira].
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However, with the gradual reduction of drug 
dosage, there were reappearance of diffuse pustules and 
crustal lesions in chest, cervical, thoracic and lumbar 
regions. In addition to these lesions, the appearance of 
nasal erythema (Figure 3A), blepharitis (Figure 3B), 
apathy and fever (39.9°C) were observed.
With the appearance of such lesions, it was sus-
pected that the patient was developing drug-triggered 
pemphigus foliaceous. The topical treatment of ocular 
lesions with 0.1% tacrolimus (Protopic®)2 associated 
with systemic treatment with 1.2 mg kg-1, SID, of 
prednisolone (Alcort®)3. The patient improved the der-
matological clinical picture, however, some side effects 
have already become evident, such as the presence of 
telangiectasia, polyuria, polyphagia and polydipsia. 
Heterodox therapy based on the use of 2 mg kg-1, SID, 
of azathioprine (Imuran®)4 was chosen in order to 
reduce corticoid dose. After 3 days of therapy, blood 
sample was collected for hepatic evaluation, detecting 
hepatotoxicity. The hemato-biochemical parameters 
are represented in Table 1.
From the results, azathioprine therapy was 
suspended, and a dose of 1.5 mg kg-1, SID, of pred-
nisolone was maintained. The patient presented a 
considerable improvement in the lesion after 10 days of 
treatment, with remission of lesions almost all over the 
body and reduction of size, frequency and amount of 
pustules. The side effects observed with the use of the 
medication in high dose involved the same previously 
mentioned, besides the presence of pendular abdomen 
and weakness in respiratory muscles, being reflected 
in a clinical picture of mild dyspnea.
After a new corticoid dose reduction, it was 
possible to perform cutaneous biopsy of an intact 
pustule, and this material was submitted to histopatho-
logical examination. The report revealed the presence 
of subcorneal pustule, with presence of acantholytic 
epithelial cells interspersed by a large number of intact 
neutrophils (Figure 2B). The microscopic aspect of 
the lesion, along with the clinical findings and other 
complementary tests, revealed a clinical picture com-
patible with Canine Pemphigus Foliaceus. The patient 
continues to follow up until the present moment where 
it is perceived that, with low doses of immunosuppres-
sive therapy, there is recurrence of the lesions.
DISCUSSION
The clinical case described demonstrates the 
occurrence of pemphigus foliaceous due to pharma-
codermic reaction after topical administration of Mu-
pirocin. This disease is known as the most common 
auto-immune skin disease in dogs and involves the 
Figure 2. Cytological evaluation (A) presents inflammatory infiltrate 
caractherized by neutrophils, macrophages and acantholytic keratinocytes 
(arrow). Original magnification: 1000x. [Scale bar= 50 μm]. Skin biopsy 
revealed subcorneal pustule, with acantholytic epithelial cells interspersed 
by a large number of intact neutrophils. H&E, Original magnification: 100x 
(B) and 400x (C). [Scale bar= 50 μm]. [Source: T.C. Ferreira].
Figure 3. Skin lesions in nasal planum (A) and eye (B). [Source: T.C. 
Ferreira].
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synthesis of antikeratinocyte autoantibodies [3,14,15]. 
The clinical suspicion was based on the clinical-cyto-
logical patterns coincident with the administration of 
the medication, where the dermatological lesions, such 
as urticaria and pruritus, were compatible with those 
previously described [19].
There have been reports that pharmacodermic 
reactions may be associated with the development of 
autoimmune diseases, such as pemphigus foliaceus 
and vulgaris. In some cases, the lesions regress after 
drug discontinuation. In others, the medication acts as 
a triggering factor, activating the genetic predisposition 
of patient, which develops the pathology even after 
therapy interruption [5,18]. The drug related PF is a 
well-recognized disease in humans [24], however this 
disease is limited to sporadic cases in dogs [14,20,23]. 
At the authors knowledge, this is the first report of 
Mupirocin as a PF triggering factor.
For diagnostic help regarding pharmacoder-
mia, a clinic algorithm was used. This method is based 
on a questionnaire which, according to the answers, 
it generates a final score, in order to try to establish a 
causal relationship between the use of the drug and the 
clinical signs presented by the pacient [12]. The ratio 
of the 10 questions analyzed provided a score of 07, 
which characterizes the drug administration as a prob-
able cause of lesions. In order to acquire a larger score, 
which would define the cause of pharmacodermic 
reaction, the drug should be readministered. However, 
such procedure has not been performed aiming at the 
health integrity of patient.
Cytological evaluation and bacterial culture of 
the material obtained from the secretion of meliceric 
crusts and epidermal collars were performed. The cytol-
ogy content (Figure 2A) was similar to that reported in 
patients with a pemphigus-like reaction to a drug [2,20]. 
Regarding bacterial culture, such test was requested 
for differential diagnosis of pyoderma. However, there 
was no bacterial growth, reinforcing the hypothesis of 
Mupirocin as causal agent of pemphigus-like lesions.
In pemphigus foliaceus, acantholysis occurs in 
superficial skin layers, culminating with vesico-bullous 
lesions that can be easily broken [4]. Such fragility 
present in pustules delays the diagnostic process due 
to absence of intact blisters that allow the correct his-
topathological evaluation, which would justify the late 
accomplishment of such complementary test. Inside 
the pustules it is possible to verify the presence of 
acantholytic cells, surrounded by neutrophils (Figure 
2B/2C). This data may indicate the cell migration from 
dermis to epidermis induced by chemotactic molecules 
from complement activation, culminating with tissue 
damage [17]. In addition, the damage that leads to 
acantholytic cells formation may also be originated 
from complement activation and antigen-antibody 
interaction over keratinocytes [3].
The adopted treatment during the clinical 
picture of pharmacodermia was based on the use of 
immunomodulatory drugs administered orally and 
topically. After 07 days of treatment, associated with 
the suspension of Mupirocin, the skin already presented 
clinical improvement (Figure 1C). Although skin lesions 
regressed early in treatment, new lesions began to appear 
Table 1. Hemato-biochemical parameters in a dog with drug-triggered pemphigus foliaceous. T0 represents the hemato-biochemical parameters before 
treatment with corticosteroids and azathioprine. T1 represents the parameters after azathioprine and low dose of corticosteroids. T2 represents the pa-
rameters after azathioprine removal and high dose of corticosteroids.
Parameter
Timeline
T0 T1 T2 Min-Max*
RBC (x106/μL) 5.5 5.9 - 5.5-8.5
Hematocrit (%) 37.3 39.3 - 37-55
WBC (x103/μL) 10.4 15.0 - 6.0-17.0
Neutrophils (U/L) 7.3 12.9 - 3.0-11.5
Total Proteins (g/dL) 10.0 8.4 - 6.0-8.0
ALT/GPT (U/L) 38.0 277.6 67.0 10.0-88.0
ALP (U/L) 32.0 981.0 174.0 20.0-150.0
BUN (mg/dL) - 104.7 65.3 21.0-60.0
*Reference [11].
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together with systemic signs such as fever and apathy. 
Such signals were only controlled through high doses 
of corticosteroids. The side effects associated with the 
continuous use of this pharmacological group involve 
tegumentary and systemic alterations [10]. Among them, 
the patient presented cutaneous thinning, telangectasia, 
polyuria, polydipsia, polyphagia and weight gain.
The use of heterodox therapies in treatment of 
autoimmune diseases aims at the reduction of cortico-
steroid doses and consequent control of adverse effects 
[10]. Among the alternative drugs, azathioprine was 
used, but it was suspended due to hepatotoxicity, so a 
high dose of corticosteroids was chosen. The patient 
followed the therapy for 10 days, with excellent post-
treatment results. The side effects developed were pre-
viously mentioned, but the patient has also presented 
frequent dyspnea due to respiratory muscle weakness.
After clinical improvement, the gradual 
reduction of steroidal therapy was started in order 
to avoid side effects related to suppression of the 
hypothalamic-pituitary-adrenal axis. This immune-
mediated disease remission was not achieved until the 
present moment, being possible to notice the recurrence 
of cutaneous lesions, although of reduced intensity, 
when the corticosteroid dose is reduced.
This report provides further evidences that 
mupirocin can cause adverse drug reaction as well as 
trigger the development of pemphigus-like lesions in 
dogs. This case also reinforces the need to understand 
the mechanism of topical drug-triggered PF in order 
to ensure appropriate diagnosis and treatment.
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